(Q44603334)

4 December 2017

0 references

Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children (English)

1 reference

methicillin-resistant Staphylococcus aureus

4 December 2017

main subject

0 references

linezolid

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

Methicillin Resistance

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520144

16 March 2024

1

Sheldon L Kaplan

1 reference

4 December 2017

Behnoosh Afghani

2

1 reference

4 December 2017

Pio Lopez

3

1 reference

4 December 2017

Elba Wu

4

1 reference

4 December 2017

Dona Fleishaker

5

1 reference

4 December 2017

Barbara Edge-Padbury

6

1 reference

4 December 2017

Sharon Naberhuis-Stehouwer

7

1 reference

4 December 2017

Jon B. Bruss

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520144

16 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520144

16 March 2024

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

https://journals.lww.com/10.1097/01.inf.0000087020.75886.93

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Pediatric Infectious Disease Journal

16 March 2024

published in

1 reference

4 December 2017

volume

22

1 reference

4 December 2017

issue

9 Suppl

1 reference

4 December 2017

page(s)

S178-85

1 reference

Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System.

4 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

16 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Staphylococcus aureus infections

16 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

16 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children

16 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002.

16 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

16 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium

16 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

16 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

16 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital

16 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

16 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

16 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

16 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

16 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

16 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

16 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

16 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children

16 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

16 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children

16 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

16 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility.

16 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients

16 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Linezolid absolute bioavailability and the effect of food on oral bioavailability

16 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

16 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000087020.75886.93

16 March 2024

Identifiers

1 reference

4 December 2017

1 reference